

Estimate change	↓
TP change	↓
Rating change	↓

Bloomberg	DN IN
Equity Shares (m)	136
M.Cap.(INRb)/(USDb)	286.5 / 3.3
52-Week Range (INR)	3169 / 1781
1, 6, 12 Rel. Per (%)	4/-26/-17
12M Avg Val (INR M)	903

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
Sales	82.8	88.3	93.1
EBITDA	10.9	13.1	14.5
PAT	7.0	8.4	9.0
EPS (INR)	51.1	61.5	66.1
EPS Gr. (%)	-7.3	20.3	7.5
BV/Sh.(INR)	395.1	447.5	503.9
Ratios			
Net D:E	0.1	0.3	0.3
RoE (%)	13.7	14.6	13.9
RoCE (%)	11.9	11.5	10.4
Payout (%)	14.7	14.7	14.7
Valuations			
P/E (x)	41.0	34.1	31.7
P/BV (x)	5.3	4.7	4.2
EV/EBITDA (x)	26.9	23.0	21.2
Div. Yield (%)	0.4	0.4	0.5
FCF Yield (%)	-1.7	-2.3	-1.9

Shareholding Pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	49.3	49.2	49.1
DII	23.2	23.2	19.3
FII	6.7	6.6	6.7
Others	20.9	20.9	24.9

FII includes depository receipts

CMP: INR2,100 TP: INR1,650 (-21%) Downgrade to Sell

Miss on core and rich valuation prompt a downgrade

- Deepak Nitrite (DN) reported a disappointing quarter (ex-government incentive income) in 4QFY25. EBITDA was 68% above our estimate and stood at INR3.2b (+5% YoY), while EBITDA adjusted for government incentive income was INR1.6b (18% below). EBITDAM was 14.5% (+40bp YoY), while adj. PAT was INR2b (estimate of INR1.1b, +3% YoY). EBIT margin contracted 13.1pp YoY for the AI segment, while the same expanded 160bp YoY for DPL.
- In FY25, DN faced global demand softness and pricing pressure from Chinese competition, which weighed on realizations. However, strong domestic demand and volume-led growth helped offset margin pressures. The company expanded its product portfolio, signed new contracts, and expects normalized profitability in FY26. Government incentives from the DPL Dahej project are expected to contribute INR600–700m annually until Dec'28.
- Advanced intermediates grew sequentially, aided by better demand in dyes and pigments, though agrochemicals remained weak. DPL volumes increased due to capacity additions, but prices were hit by higher imports. The commissioning of the Acetophenone asset will aid internal consumption and improve efficiency. Debottlenecking and new SKUs added in FY25 will continue into FY26.
- Several key projects are lined up in FY26—CNA, WNA, Hydrogenation, and Nitration in 2Q, and MIBK/MIBC in 3Q. DN's INR85b investment in Phenol, Acetone, and Polycarbonate Resin capacities is backed by technology tie-ups. Renewable energy is expected to meet 60% of power needs by the end of FY27, enabling a 60% CO₂ reduction for DN. While no quarterly guidance has been given, management remains cautiously optimistic for FY26.
- Due to the underperformance and weak guidance, we cut our EBITDA/EPS estimates by 10%/8% for FY26 and by 12%/11% for FY27. Our EBITDAM stands at 14.9%/15.6% for FY26E/27E. There is a risk of further downgrades in our estimate going forward. The stock trades at ~32x FY27E EPS of INR66.1 and at ~21x FY27E EV/EBITDA. Given the expensive valuation for a commodity chemicals company, **we downgrade our rating for DN to Sell**, valuing the stock at 25x FY27E EPS to arrive at our TP of INR1,650.

Miss on EBITDA (excluding govt. incentive income)

- Revenue stood at INR21.8b (our est. INR19.2b, up 3% YoY). This included a government incentive income of INR1.6b. EBITDA stood at INR3.2b (our est. of INR1.9b, up 5% YoY). EBITDA adjusted for government incentive income was INR1.6b (18% below our estimate). **Gross margin came in at 30.6% (down 10bp YoY), while EBITDAM stood at 14.5% (vs. 14.2% in 4QFY24).** Adj. PAT stood at INR2b (our est. of INR1.1b, up 3% YoY).
- In FY25, revenue was at INR82.8b (+8% YoY), EBITDA at INR10.9b (-2% YoY), and reported PAT at INR7b (-14% YoY). **EBITDAM was at 13.2% (-140bp YoY).**
- The BoD approved a final dividend of INR7.5/share for FY25. It also approved the appointment of Shri Subimal Mondal as Group CHRO w.e.f. 28th May'24 for a period of three years. He has 39 years of experience and was last associated with IOCL, where he retired as the ED (HR).

Segmental details

- Phenolics' EBIT margin stood at 15.6%, with EBIT at INR2.4b. Advanced Intermediates' (AI) EBIT margin was at 6.9%, with EBIT at INR449m. The revenue mix of Phenolics stood at 70% in 4QFY25, with the Advanced Intermediates share at 30%. The EBIT mix for AI was down to 16% from 39% in 4QFY24. Contribution from Phenolics stood at 84% (vs. 61% in 4QFY24).
- In FY25, AI's revenue stood at INR25.3b (-7% YoY), while DPL's revenue stood at INR58.1b (+16% YoY). AI's EBIT was at INR1.8b (-61% YoY), while DPL's EBIT was at INR7.8b (+22% YoY). AI's EBIT margin was at 7% (-940bp YoY), while DPL's EBIT margin was at 13.5% (+60bp YoY).


Valuation and view

- DN aims to become the largest player in the solvent market by focusing on import substitution. It is foraying into PC (165ktpa), Methyl Isobutyl Ketone (MIBK, 40ktpa), Methyl Isobutyl Carbinol (MIBC, 8ktpa), and Sodium Nitrite/Nitrate, among other products. These products are taking shape and are likely to be commissioned in FY26. Some other previously announced capex projects have already been commissioned (fluorination plant, specialty salts unit).
- DN is aggressively pursuing both backward and forward integration projects to de-risk its business model and expand its product portfolio. However, its entire product portfolio consists of commodities and does not warrant such a high valuation. The stock trades at expensive valuations of ~32x FY27E EPS of INR66.1 and ~21x FY27E EV/EBITDA. **Hence, we downgrade the stock to Sell with a TP of INR1,650 (premised on 25x FY27E EPS).**

Y/E March	Consolidated - Quarterly Snapshot (INR m)											
	FY24				FY25				FY24	FY25	FY25	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		4QE	(%)	
Gross Sales	17,683	17,781	20,092	21,262	21,668	20,320	19,034	21,797	76,818	82,819	19,184	14%
YoY Change (%)	-14.1	-9.4	0.9	8.4	22.5	14.3	-5.3	2.5	-3.6	7.8	-9.8	
Gross Margin (%)	30.8%	34.4%	31.7%	30.7%	30.8%	32.0%	26.8%	30.6%	31.8%	30.1%	27.9%	2.7%
EBITDA	2,098	3,023	3,047	3,011	3,092	2,975	1,685	3,166	11,178	10,918	1,888	68%
Margin (%)	11.9	17.0	15.2	14.2	14.3	14.6	8.9	14.5	14.6	13.2	9.8	4.7
Depreciation	381	394	417	465	475	485	482	513	1,657	1,954	505	
Interest	18	27	29	44	58	63	61	93	118	275	100	
Other Income	319	170	136	191	188	213	210	228	816	839	211	
PBT	2,017	2,772	2,736	3,492	2,748	2,640	1,352	2,788	11,017	9,528	1,494	87%
Tax	518	721	715	953	723	698	371	762	2,908	2,554	399	
Rate (%)	25.7	26.0	26.1	27.3	26.3	26.4	27.4	27.3	26.4	26.8	26.7	
Reported PAT	1,499	2,051	2,020	2,538	2,025	1,942	981	2,025	8,108	6,974	1,095	85%
Adj PAT	1,499	2,051	2,020	1,958	2,025	1,942	981	2,025	7,521	6,974	1,095	85%
YoY Change (%)	-36.1	17.5	-3.4	-16.3	35.1	-5.3	-51.4	3.4	-11.7	-7.3	-44.1	
Margin (%)	8.5	11.5	10.1	9.2	9.3	9.6	5.2	9.3	9.8	8.4	5.7	3.6
Segmental Revenue (INR m)												
Advanced Intermediates	7,083	6,702	6,743	6,711	7,157	6,060	5,517	6,539	23,036	23,266	6,326	3%
Phenolic	10,679	11,201	13,493	14,661	14,636	14,435	13,657	15,323	36,356	34,194	12,965	18%
Segmental EBIT (INR m)												
Advanced Intermediates	1,149	1,034	937	1,339	665	475	169	449	4,224	3,989	321	40%
Phenolic	876	1,704	1,798	2,061	2,076	2,149	1,212	2,393	4,067	3,917	1,080	122%
Segmental EBIT Margin (%)												
Advanced Intermediates	16.2%	15.4%	13.9%	20.0%	9.3%	7.8%	3.1%	6.9%	18.3%	17.1%	5.1%	1.8%
Phenolic	8.2%	15.2%	13.3%	14.1%	14.2%	14.9%	8.9%	15.6%	11.2%	11.5%	8.3%	7.3%


4QFY25 in charts

Exhibit 1: Contribution of Phenolics to total revenue increased to 70% in 4QFY25 from 69% in 4QFY24...




Source: Company, MOFSL

Exhibit 2: ...while Phenolics' contribution to the EBIT mix improved to 84% from 61% in 4QFY24




Source: Company, MOFSL

Exhibit 3: Sales up 3% YoY




Source: Company, MOFSL

Exhibit 4: Margins expanded QoQ




Source: Company, MOFSL

Exhibit 5: EBITDA up 5% YoY




Source: Company, MOFSL


Exhibit 6: Reported PAT was down 20% YoY




Source: Company, MOFSL

Exhibit 7: Revenue from AI declined 3% YoY...



Source: Company, MOFSL

Exhibit 8: ...with a 13.1pp YoY contraction in EBITM...


Source: Company, MOFSL

Exhibit 9: Revenue from DPL increased 5% YoY...


Source: Company, MOFSL

Exhibit 10: ...with EBITM at 15.6% (up 160bp YoY)


Source: Company, MOFSL



Key highlights from the management commentary

- The global slowdown in demand and macro uncertainties put pressure on intermediate prices
- Intense price competition from Chinese players puts pressure on margins
- Domestic demand served as a vital cushion and showed early signs of demand revival
- Expanded product portfolio and signed new contracts in FY25
- Several projects commissioning on the horizon in FY26
 - CNA, WNA, Hydrogenation, Nitration in 2Q
 - MIBK/MIBC in 3Q
- Have started gaining benefits via renewable energy which would serve 60% of total power consumption by end-FY27
 - This would also help in a 60% reduction in CO₂ emissions
- Revenue growth was mainly led by volume, which offset subdued realization in FY25
- Government incentive income is the normal course of business for the DPL project set up in Dahej
 - Guidance of ~INR600-700m every year on an average for 10 years
- The normalized level of profitability to be expected in FY26
- Advanced Intermediates (AI)
 - Strong performance across product segments led to sequential growth in the segment
 - Demand from dyes and pigments has improved from 3Q end but pricing pressure persists
 - Agrochem demand remains subdued- trend to persist for the next couple of quarters
 - DNL has debottlenecked its OBA capacity and has added new SKUs in FY25; looks to further debottleneck capacity in FY26
- DPL
 - Increased volume due to capacity augmentation during the year
 - The temporary rise in imports led to subdued prices that started in 3QFY25
 - Commissioning of Acetophenone asset to support captive consumption
- Future outlook
 - Major upcoming capacity additions in Phenol, Acetone, and IPA to support Polycarbonate Resin (capex of INR85b) production
 - Technology tie-ups have been done w.r.t. new Phenol plants and also for the Bisphenol-A (BPA) project
 - Supportive policy environment, shift from high-cost regions, and growing domestic demand to drive long-term growth
- Management for the first time won't give guidance for the ensuing quarter but is cautiously optimistic for FY26.

Financial story in charts

Exhibit 11: Revenue contribution from Phenol to remain higher...




Exhibit 12: ...with a focus on the domestic market as a play on import substitution






Exhibit 13: Segmental EBIT breakdown of DN...




Source: MOFSL

Exhibit 14: ...with DPL enjoying a higher EBITM




Source: Company, MOFSL

Exhibit 15: EBITDAM to normalize from FY22 levels




Source: Company, MOFSL

Exhibit 16: Expect ~14% PAT CAGR over FY25-27




Source: Company, MOFSL

Exhibit 17: Capex to be incurred by DN



Source: Company, MOFSL

Exhibit 18: Debt profile of DN



Source: Company, MOFSL

Financials and valuations

Consolidated - Income Statement								(INR m)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	42,297	43,598	68,022	79,721	76,818	82,819	88,257	93,123
Change (%)	56.7	3.1	56.0	17.2	-3.6	7.8	6.6	5.5
Gross Margin (%)	43.9	48.1	39.5	32.9	31.8	30.1	32.0	32.8
EBITDA	10,258	12,470	16,036	12,894	11,233	10,918	13,116	14,549
Margin (%)	24.3	28.6	23.6	16.2	14.6	13.2	14.9	15.6
Depreciation	1,397	1,526	1,777	1,663	1,657	1,954	2,386	2,961
EBIT	8,861	10,944	14,259	11,231	9,576	8,964	10,730	11,589
Int. and Finance Charges	1,149	742	340	248	118	275	380	449
Other Income	352	215	426	476	761	839	861	908
PBT bef. EO Exp.	8,064	10,417	14,345	11,459	10,219	9,528	11,210	12,047
EO Items	0	0	0	0	798	0	0	0
PBT after EO Exp.	8,064	10,417	14,345	11,459	11,017	9,528	11,210	12,047
Total Tax	1,954	2,659	3,678	2,939	2,908	2,554	2,822	3,032
Tax Rate (%)	24.2	25.5	25.6	25.6	26.4	26.8	25.2	25.2
Minority Interest	-	-	-	-	0	-	-	-
Reported PAT	6,110	7,758	10,666	8,520	8,109	6,974	8,389	9,015
Adjusted PAT	6,110	7,758	10,666	8,520	7,522	6,974	8,389	9,015
Change (%)	251.9	27.0	37.5	-20.1	-11.7	-7.3	20.3	7.5
Margin (%)	14.4	17.8	15.7	10.7	9.8	8.4	9.5	9.7

Consolidated - Balance Sheet								(INR m)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	273	273	273	273	273	273	273	273
Total Reserves	15,446	23,194	33,112	40,627	47,693	53,614	60,772	68,465
Net Worth	15,719	23,467	33,384	40,900	47,966	53,887	61,045	68,737
Minority Interest	-	-	-	-	261	360	360	360
Total Loans	10,279	5,775	3,007	545	2,170	11,705	18,728	26,220
Deferred Tax Liabilities	796	1,078	1,229	1,566	1,736	2,128	2,128	2,128
Capital Employed	26,794	30,320	37,620	43,011	52,133	68,080	82,261	97,445
Gross Block	20,460	22,441	25,263	26,523	31,690	35,262	52,006	68,749
Less: Accum. Deprn.	2,140	3,666	5,443	7,106	8,763	10,717	13,102	16,063
Net Fixed Assets	18,320	18,774	19,820	19,416	22,927	24,546	38,903	52,686
Goodwill on Consolidation	-	-	-	-	-	27	27	27
Capital WIP	1,723	2,068	1,037	3,008	7,735	16,491	16,491	16,491
Total Investments	24	1,893	4,390	3,794	1,219	5,109	5,109	5,109
Curr. Assets, Loans, and Adv.	12,019	12,868	19,057	25,069	29,081	31,004	31,318	33,196
Inventory	3,945	3,827	5,846	8,931	7,599	9,264	9,681	10,124
Account Receivables	6,127	7,563	11,291	13,095	12,984	12,738	13,574	14,323
Cash and Bank Balance	314	334	418	400	4,655	4,066	2,809	3,214
Cash	21	89	229	376	2,380	1,794	538	942
Bank Balance	293	245	189	23	2,275	2,272	2,272	2,272
Loans and Advances	1,633	1,144	1,503	2,644	3,844	4,937	5,253	5,536
Curr. Liability and Prov.	5,292	5,283	6,684	8,277	8,829	9,097	9,586	10,063
Account Payables	3,643	4,367	5,117	6,618	5,823	5,217	5,452	5,702
Other Current Liabilities	1,385	640	1,272	1,216	2,476	3,259	3,473	3,664
Provisions	264	276	296	443	531	620	661	698
Net Current Assets	6,727	7,585	12,373	16,792	20,252	21,908	21,732	23,133
Appl. of Funds	26,794	30,320	37,620	43,011	52,133	68,080	82,261	97,445

Financials and valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	44.8	56.9	78.2	62.5	55.1	51.1	61.5	66.1
EPS Growth (%)	252%	27%	37%	-20%	-12%	-7%	20%	7%
Cash EPS	55.0	68.1	91.2	74.7	67.3	65.5	79.0	87.8
BV/Share	115.2	172.0	244.8	299.9	351.7	395.1	447.5	503.9
DPS	4.5	5.5	7.0	7.5	7.5	7.5	9.0	9.7
Payout (%)	12.1	9.7	9.0	12.0	12.6	14.7	14.7	14.7
Valuation (x)								
P/E	46.8	36.9	26.8	33.6	38.0	41.0	34.1	31.7
Cash P/E	38.1	30.8	23.0	28.1	31.1	32.0	26.5	23.9
P/BV	18.2	12.2	8.6	7.0	6.0	5.3	4.7	4.2
EV/Sales	7.0	6.7	4.2	3.6	3.7	3.5	3.4	3.3
EV/EBITDA	28.8	23.4	18.0	22.2	25.2	26.9	23.0	21.2
Dividend Yield (%)	0.2	0.3	0.3	0.4	0.4	0.4	0.4	0.5
FCF per share	25.6	57.8	46.8	21.3	8.0	-36.2	-48.9	-39.0
Return Ratios (%)								
RoE	46.2	39.6	37.5	22.9	16.9	13.7	14.6	13.9
RoCE	27.6	29.1	32.1	21.6	16.0	11.9	11.5	10.4
RoIC	28.0	32.1	36.7	24.7	19.0	16.2	16.0	13.3
Working Capital Ratios								
Fixed Asset Turnover (x)	2.4	2.4	3.5	4.1	3.6	3.5	2.8	2.0
Asset Turnover (x)	1.6	1.4	1.8	1.9	1.5	1.2	1.1	1.0
Inventory (Days)	34	32	31	41	36	41	40	40
Debtor (Days)	53	63	61	60	62	56	56	56
Creditor (Days)	31	37	27	30	28	23	23	22
Leverage Ratio (x)								
Current Ratio	2.3	2.4	2.9	3.0	3.3	3.4	3.3	3.3
Interest Coverage Ratio	7.7	14.7	41.9	45.3	80.9	32.6	28.2	25.8
Net Debt/Equity ratio	0.6	0.2	0.1	0.0	-0.1	0.1	0.3	0.3

Consolidated - Cash Flow Statement

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
(INR m)								
OP/(Loss) before Tax	8,064	10,417	14,345	11,459	11,017	9,528	11,210	12,047
Depreciation	1,397	1,526	1,777	1,663	1,657	1,954	2,386	2,961
Others	1,262	852	295	63	-509	-285	380	449
Direct Taxes Paid	-1,985	-2,365	-3,535	-2,600	-2,665	-2,152	-2,822	-3,032
(Inc.)/Dec. in WC	-1,092	-412	-4,643	-4,085	-720	-2,798	-1,080	-997
CF from Operations	7,647	10,019	8,239	6,499	8,781	6,247	10,074	11,428
(Inc.)/Dec. in FA	-4,160	-2,140	-1,862	-3,599	-7,685	-11,191	-16,743	-16,743
Free Cash Flow	3,487	7,879	6,377	2,900	1,096	-4,944	-6,669	-5,315
Change in Investments	3	-1,854	-2,401	816	427	-4,059	0	0
Others	-122	33	22	22	40	337	0	0
CF from Investments	-4,279	-3,961	-4,241	-2,761	-7,218	-14,913	-16,743	-16,743
Issue of Shares	0	0	0	0	0	102	0	0
Inc.-(Dec.) in Debt	-1,088	-5,246	-2,812	-2,523	1,625	9,277	7,023	7,491
Interest Paid	-1,134	-736	-320	-233	-98	-194	-380	-449
Dividend Paid	-1,060	-4	-750	-955	-1,023	-1,023	-1,231	-1,322
Others	-94	-5	24	120	-68	-100	0	0
CF from Fin. Activity	-3,376	-5,990	-3,858	-3,591	435	8,062	5,412	5,719
Inc./Dec. in Cash	-8	68	139	148	1,998	-605	-1,257	404
Opening Balance	30	22	90	229	377	2,380	1,795	538
Closing Balance	22	90	229	377	2,380	1,795	538	943

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20Companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
 7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
 8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
 9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
 10. MOFSL has not engaged in market making activity for the subject company.
-

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.